Epstein Secrets

President-elect, outgoing Trump officials can't share critical COVID vaccine distribution plans with the incoming Biden team." Biden Chief of Staff Ron Klain: "The sooner we can get our transition experts into meetings with the folks who are planning the vaccination campaign, the more seamless the transi

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

President-elect, outgoing Trump officials can't share critical COVID vaccine distribution plans with the incoming Biden team." Biden Chief of Staff Ron Klain: "The sooner we can get our transition experts into meetings with the folks who are planning the vaccination campaign, the more seamless the transi

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

President-elect, outgoing Trump officials can't share critical COVID vaccine distribution plans with the incoming Biden team." Biden Chief of Staff Ron Klain: "The sooner we can get our transition experts into meetings with the folks who are planning the vaccination campaign, the more seamless the transi

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying